scispace - formally typeset
G

Gerald Willimsky

Researcher at Charité

Publications -  43
Citations -  3028

Gerald Willimsky is an academic researcher from Charité. The author has contributed to research in topics: Antigen & Immune system. The author has an hindex of 21, co-authored 37 publications receiving 2526 citations. Previous affiliations of Gerald Willimsky include Max Delbrück Center for Molecular Medicine & Humboldt University of Berlin.

Papers
More filters
Journal ArticleDOI

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

Andrea Cossarizza, +462 more
- 01 Oct 2019 - 
TL;DR: These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community providing the theory and key practical aspects offlow cytometry enabling immunologists to avoid the common errors that often undermine immunological data.
Journal ArticleDOI

Guidelines for the use of flow cytometry and cell sorting in immunological studies

Andrea Cossarizza, +246 more
- 01 Oct 2017 - 
TL;DR: A rapid search in PubMed shows that using "flow cytometry immunology" as a search term yields more than 68 000 articles, the first of which is not about lymphocytes as mentioned in this paper.
Journal ArticleDOI

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance

Gerald Willimsky, +2 more
- 01 Sep 2005 - 
TL;DR: It is shown, by generating a mouse model of sporadic cancer based on rare spontaneous activation of a dormant oncogene, that immunogenic tumours do not escape their recognition but induce tolerance and the data argue against immunosurveillance of spontaneous cancer.
Journal ArticleDOI

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.

Shabnam Shalapour, +15 more
- 07 May 2015 - 
TL;DR: Mouse B cells modulate the response to low-dose oxaliplatin, which promotes tumour-directed CTL activation by inducing immunogenic cell death, and shows that mouse prostate cancer models were refractory to oxali Platin unless genetically or pharmacologically depleted of B cells.
Journal ArticleDOI

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.

Gerald Willimsky, +7 more
- 07 Jul 2008 - 
TL;DR: Tolerance to the tumor antigen occurs at the premalignant stage, tumor latency is unlikely caused by CTL control, and a persistent immunogenic tumor antigen causes general CTL unresponsiveness but tumor burden and iMCs per se do not.